About GA-40 In Brief
ALEXIS developed special tests that reveal new, biologically active plant origin natural peptides, possessing characteristics of human cytokines (a class of immuno-regulatory peptides, that are secreted by cells of the immune system). The new innovative immunotherapeutic and anti-cancer medicine, GA-40, is one of our patented products derived from this powerful discovery.
GA-40 is a complex of natural peptides obtained from ecologically pure raw materials of plant origin. It represents a standardized combination of peptides identified by biochemical and chromatographically methods. In medical practice it is used as colorless injection solution.
GA-40 is patented (Patent P 2256).
GA-40 is registered in :
Georgia –registration: № R- 014515, № R-015768, Immunomodulator code: LO3A and Antineoblastic, code: L01C;
Ukraine – registration: № UA/6435/01/01, Immunomodulator code: LO3A and Antineoblastic, code: L01C;
Kyrgyzstan –registration: ser. P-2019-583 KP, № 7770, Immunomodulator code: LO3A and Antineoblastic, code: L01C;
Russian Federation – issued a preregistration certificate, RegNx: 114917 RegWorkNx: 55746. AS.
GA-40 has passed preclinical and clinical trials in following organizations:
· Medical & Biological Scientific Research Centre – Company;
· Research Laboratory of Biomedical Technologies, St. Andrew the First-Called Georgian University of the Patriarchate of Georgia;
· Gvamichava National Centre of Oncology of Georgia;
· Clinical and Experimental Research Institute of Tbilisi State Medical University;
· Tbilisi №1 Dispensary for Skin and Venereal Diseases of the Ministry of Healthcare of Georgia;
· Institute of Experimental Pathology, Oncology, and Radiobiology at the National Academy of Sciences of Ukraine;
· Department of Biochemistry of Ukrainian State University;
· Bukovin State Medical University of Ukraine;
· Centre of Oncology of Ukrainian Medical Academy;
· Laboratory of Cell Signal Mechanisms of the I.Paladin Institute of Biochemistry at Ukrainian Medical Academy;
· Medical Research Institute of Physical Chemistry at the Ministry of Healthcare of Russian Federation;
· Pharmacological Department of the Medical University of Russian Federation;
· Research Institute of the Otsuka Pharmaceutical Co., Japan Tokushima Cell Technology Institute, Japan;
· Fuji Memorial Institute of the Preclinical Research, Bivako/Japan;
· Hanoi Research Center of Cancer Research Laboratories, Japan;
· Tokushima Otsuka Immunology Research Institute, Japan;
· Tokushima Institute of New Drug Research and Safety Evaluation, Japan;
· University of Washington, School of Medicine, Cancer Research laboratory, Department of Pathology, Seattle, USA.
The results on GA-40 Preclinical and Clinical Trials given in GA-40’s three dissertation works:
· Dissertation for PhD of medical science. Lisenko S. A. “GA-40’s effects on cancer micro-circulator channel distribution”. The dissertation is 170 pages long. 17 articles have been published based on this dissertation. Kavecki Institute of experimental oncology, and radio-biology. Kiev, Ukraine.
· Dissertation for PhD of medical science. Popovich, A. B. “Liver and kidney functional-structural changes with severe hypoxia”. Dissertation is 205 pages long. 14 scientific articles have been published based on this dissertation. I. I. Gorbachovski Ternopol state medical university. Ternopol, Ukraine, 2010.
· Dissertation for PhD of medical science. B.G. Savka. “”Liver functional—morphological behavior with interstitial tubule disease”. Dissertation is 170 pages long. 15 articles have been published based on this dissertation. Bukuvinski state medical university of Ukraine. Chernovci, Ukraine, 2010.
The results on GA-40 Preclinical and Clinical Trials given in two books:
· Giorgi Alexidze. “A New Immunotherapeutic and Anti-cancer Drug GA-40”. Book, LAMBERT Academic Publishing. Germany, 588pp. 2014.
· Pishak, V. P., Rogov M. V. “Chronical Nephritic Pathophisiology”. Book, Chernivci, “Mistro”, 1008, 168 pages, 2011.
The results on GA-40 Preclinical and Clinical Trials given in 65 scientific publications and in more than 18 GA-40 Preclinical and Clinical trials conclusions.
Preclinical and clinical studies showed that GA-40, like some cytokines formed in organisms, (Tumor necrosis factor and Interferon’s) possesses strong immune-modulating and anti-cancer properties. Like anticancer agents, GA-40 is characterized by direct and specific cytotoxic action on malignant tumor cells without negatively impacting the normal cells of an organism.
As shown in Preclinical and Clinical trials GA-40 is distinguished by its GA-40 direct action and induction differentiation of human myeloid leukemia cells (HL-60) into non-growing mature myeloid cells.
GA-40 is an immune system modulator, possessing immunity-correcting properties that actually correct the status of a patient’s immune system. GA-40 normalizes the quantitative and functional characteristics of the T and B immune systems, in particular T-helper, T-cytotoxic, natural killer (NK-cells), macrophages, granulocytes and also normalizes the CD4/CD8 ratio and cytokine production (TNF-α, INF-y).
Anti-cancer action of GA-40 is caused also by its anti-angiogenesis property. GA-40 Inhibits the release of vascular epithelial cell growth factor (VEGF) by cancer cells.
GA-40 treatments show positive effects on clinical, hematological and biochemical indices and does not induce the formation of antibodies against GA-40 in the body of cancer patients.
GA-40 is absolutely harmless for the organism. The study of GA- 40's effect using a wide spectrum of research methods (toxicological, pathomorphological, physiological, biological, histostructural, pathophysiological and immunological ones) and it was established that GA-40 does not cause local irritant or allergic effects, acute or chronic toxicoses, specific types of chronic toxicity, mutagenic activity, cumulation, reproductive toxicity, embryo toxicity, local irritants, changes in integral indices, biochemical indices, peripheral blood indices, immunotoxicity, allergic reactions, general anaphylaxis, supersensitive reactions, cytogenic and mutagenic activities, slow type supersensitive reactions, impact on the complementary system, development of normal antibodies, impact on Con-A induced inflammatory processes and generative functions of the body.
GA-40 does not cause a violation of adipose or alter carbohydrate metabolism. It does not impact or alter the cardiovascular and respiratory systems, or the ability of an organism to produce normal antibodies and does not induce the formation of antibodies against GA-40, the aspect and localization of organs, the histological structure of the lungs, renal, liver, bowels, heart, liver, spleen, intestines, pancreas, central nervous system (behavior) and other tissues of the body, as well as the alterations in body temperature and blood pressure.
GA-40 has 8 powerful effects in the body.
6 of those are attacks on cancer.
8. GA-40 shows anti-oxidant activity and thus causes neutralization of free radicals in the body, decrease intoxication and side effects caused by the treatment of chemo and radiotherapy.
· GA-40 has no side effect, no contraindications and accordingly is completely harmless for the patients.
• First stage: monotherapy with GA-40 when the size of tumor is not more than 1 cm, causing a complete regression of the tumor. If the tumor size over 1 cm, permanent and long-term monotherapy with GA-40 or in combination with chemo/radiotherapy before surgery provides the regression of the latent metastasis, reduced growth of primary tumor, stabilization and partial reduction in size. This treatment ensures the transfer of patients in operable condition, when with high probability exclude the occurrence of relapses. The monotherapy GA-40 after surgery virtually eliminates recurrences.
• The second and third stages: monotherapy with GA-40 or in combination with chemo or radio therapy causes complete regression of latent and fixed metastasis, a suspension of growth of a primary tumor and partial regression, localization and translation of the patient in operable condition. Permanent and long-term monotherapy (or in combination with chemo - and radiotherapy) in most cases causes complete regression of the tumor and complete recovery.
• Fourth stage: in cases of patients with advanced, incurable cancer, when the patient is refused all conventional methods of cure, prolonged application of GA-40 improve of quality of life and life extension.
Our hope is that you discover how effective GA-40 can be in enhancing your body’s immune system and fighting cancer and other serious diseases.
GA-40 is a complex of natural peptides obtained from ecologically pure raw materials of plant origin. It represents a standardized combination of peptides identified by biochemical and chromatographically methods. In medical practice it is used as colorless injection solution.
GA-40 is patented (Patent P 2256).
GA-40 is registered in :
Georgia –registration: № R- 014515, № R-015768, Immunomodulator code: LO3A and Antineoblastic, code: L01C;
Ukraine – registration: № UA/6435/01/01, Immunomodulator code: LO3A and Antineoblastic, code: L01C;
Kyrgyzstan –registration: ser. P-2019-583 KP, № 7770, Immunomodulator code: LO3A and Antineoblastic, code: L01C;
Russian Federation – issued a preregistration certificate, RegNx: 114917 RegWorkNx: 55746. AS.
GA-40 has passed preclinical and clinical trials in following organizations:
· Medical & Biological Scientific Research Centre – Company;
· Research Laboratory of Biomedical Technologies, St. Andrew the First-Called Georgian University of the Patriarchate of Georgia;
· Gvamichava National Centre of Oncology of Georgia;
· Clinical and Experimental Research Institute of Tbilisi State Medical University;
· Tbilisi №1 Dispensary for Skin and Venereal Diseases of the Ministry of Healthcare of Georgia;
· Institute of Experimental Pathology, Oncology, and Radiobiology at the National Academy of Sciences of Ukraine;
· Department of Biochemistry of Ukrainian State University;
· Bukovin State Medical University of Ukraine;
· Centre of Oncology of Ukrainian Medical Academy;
· Laboratory of Cell Signal Mechanisms of the I.Paladin Institute of Biochemistry at Ukrainian Medical Academy;
· Medical Research Institute of Physical Chemistry at the Ministry of Healthcare of Russian Federation;
· Pharmacological Department of the Medical University of Russian Federation;
· Research Institute of the Otsuka Pharmaceutical Co., Japan Tokushima Cell Technology Institute, Japan;
· Fuji Memorial Institute of the Preclinical Research, Bivako/Japan;
· Hanoi Research Center of Cancer Research Laboratories, Japan;
· Tokushima Otsuka Immunology Research Institute, Japan;
· Tokushima Institute of New Drug Research and Safety Evaluation, Japan;
· University of Washington, School of Medicine, Cancer Research laboratory, Department of Pathology, Seattle, USA.
The results on GA-40 Preclinical and Clinical Trials given in GA-40’s three dissertation works:
· Dissertation for PhD of medical science. Lisenko S. A. “GA-40’s effects on cancer micro-circulator channel distribution”. The dissertation is 170 pages long. 17 articles have been published based on this dissertation. Kavecki Institute of experimental oncology, and radio-biology. Kiev, Ukraine.
· Dissertation for PhD of medical science. Popovich, A. B. “Liver and kidney functional-structural changes with severe hypoxia”. Dissertation is 205 pages long. 14 scientific articles have been published based on this dissertation. I. I. Gorbachovski Ternopol state medical university. Ternopol, Ukraine, 2010.
· Dissertation for PhD of medical science. B.G. Savka. “”Liver functional—morphological behavior with interstitial tubule disease”. Dissertation is 170 pages long. 15 articles have been published based on this dissertation. Bukuvinski state medical university of Ukraine. Chernovci, Ukraine, 2010.
The results on GA-40 Preclinical and Clinical Trials given in two books:
· Giorgi Alexidze. “A New Immunotherapeutic and Anti-cancer Drug GA-40”. Book, LAMBERT Academic Publishing. Germany, 588pp. 2014.
· Pishak, V. P., Rogov M. V. “Chronical Nephritic Pathophisiology”. Book, Chernivci, “Mistro”, 1008, 168 pages, 2011.
The results on GA-40 Preclinical and Clinical Trials given in 65 scientific publications and in more than 18 GA-40 Preclinical and Clinical trials conclusions.
Preclinical and clinical studies showed that GA-40, like some cytokines formed in organisms, (Tumor necrosis factor and Interferon’s) possesses strong immune-modulating and anti-cancer properties. Like anticancer agents, GA-40 is characterized by direct and specific cytotoxic action on malignant tumor cells without negatively impacting the normal cells of an organism.
As shown in Preclinical and Clinical trials GA-40 is distinguished by its GA-40 direct action and induction differentiation of human myeloid leukemia cells (HL-60) into non-growing mature myeloid cells.
GA-40 is an immune system modulator, possessing immunity-correcting properties that actually correct the status of a patient’s immune system. GA-40 normalizes the quantitative and functional characteristics of the T and B immune systems, in particular T-helper, T-cytotoxic, natural killer (NK-cells), macrophages, granulocytes and also normalizes the CD4/CD8 ratio and cytokine production (TNF-α, INF-y).
Anti-cancer action of GA-40 is caused also by its anti-angiogenesis property. GA-40 Inhibits the release of vascular epithelial cell growth factor (VEGF) by cancer cells.
GA-40 treatments show positive effects on clinical, hematological and biochemical indices and does not induce the formation of antibodies against GA-40 in the body of cancer patients.
GA-40 is absolutely harmless for the organism. The study of GA- 40's effect using a wide spectrum of research methods (toxicological, pathomorphological, physiological, biological, histostructural, pathophysiological and immunological ones) and it was established that GA-40 does not cause local irritant or allergic effects, acute or chronic toxicoses, specific types of chronic toxicity, mutagenic activity, cumulation, reproductive toxicity, embryo toxicity, local irritants, changes in integral indices, biochemical indices, peripheral blood indices, immunotoxicity, allergic reactions, general anaphylaxis, supersensitive reactions, cytogenic and mutagenic activities, slow type supersensitive reactions, impact on the complementary system, development of normal antibodies, impact on Con-A induced inflammatory processes and generative functions of the body.
GA-40 does not cause a violation of adipose or alter carbohydrate metabolism. It does not impact or alter the cardiovascular and respiratory systems, or the ability of an organism to produce normal antibodies and does not induce the formation of antibodies against GA-40, the aspect and localization of organs, the histological structure of the lungs, renal, liver, bowels, heart, liver, spleen, intestines, pancreas, central nervous system (behavior) and other tissues of the body, as well as the alterations in body temperature and blood pressure.
GA-40 has 8 powerful effects in the body.
6 of those are attacks on cancer.
- GA-40 directly and selectively acts on cancer cells and cause their destruction via apoptosis.
- GA-40 directly acts on Human Myeloid Leukemic cells and induces their differentiation into mature normal myeloid cells.
- Ga-40 directly acts on peripheral blood mononuclear cells and causes their activation and the subsequent secretion of tumor necrosis factor (TNF) and interferon (INF-Y). These cytokines causes destruction of cancer cells via apoptosis.
- GA-40 directly acts and activates cytotoxic-T cells, cytotoxic macrophages and cytotoxic neutrophils. These cytotoxic cells recognize, surround and destroy cancer cells.
- GA-40 indirectly activates Natural killer Cells. These NK-cells recognize, surround and destroy cancer cells.
- GA-40 is anti-angiogenesis factor, reduces the level of the vascular epithelial cell growth factor (VEGF) in the blood. Inhibits formation of new blood vessels in tumor, inhibits tumor growth and prevents spread of metastases in the body via blood circulatory system by blocking tumor angiogenesis. (efficiency above 70%).
8. GA-40 shows anti-oxidant activity and thus causes neutralization of free radicals in the body, decrease intoxication and side effects caused by the treatment of chemo and radiotherapy.
· GA-40 has no side effect, no contraindications and accordingly is completely harmless for the patients.
• First stage: monotherapy with GA-40 when the size of tumor is not more than 1 cm, causing a complete regression of the tumor. If the tumor size over 1 cm, permanent and long-term monotherapy with GA-40 or in combination with chemo/radiotherapy before surgery provides the regression of the latent metastasis, reduced growth of primary tumor, stabilization and partial reduction in size. This treatment ensures the transfer of patients in operable condition, when with high probability exclude the occurrence of relapses. The monotherapy GA-40 after surgery virtually eliminates recurrences.
• The second and third stages: monotherapy with GA-40 or in combination with chemo or radio therapy causes complete regression of latent and fixed metastasis, a suspension of growth of a primary tumor and partial regression, localization and translation of the patient in operable condition. Permanent and long-term monotherapy (or in combination with chemo - and radiotherapy) in most cases causes complete regression of the tumor and complete recovery.
• Fourth stage: in cases of patients with advanced, incurable cancer, when the patient is refused all conventional methods of cure, prolonged application of GA-40 improve of quality of life and life extension.
Our hope is that you discover how effective GA-40 can be in enhancing your body’s immune system and fighting cancer and other serious diseases.